St. Jude finds young age may give survival advantage to children with certain brain tumorsMay 30, 2008The improved survival of children under 3 years old with diffuse pontine glioma compared to older children suggests that the biological properties of this cancer may be distinct in young patients St. Jude Children's Research Hospital investigators have shown that children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same cancer. Results of the study, which appear in the advance online publication of the journal "Cancer," are important because clinicians have long believed that DPG was universally fatal. Moreover, it was assumed that clinicians had simply misdiagnosed the disease in children who responded to treatment and survived.
"Our findings show that children under 3 years with DPG can potentially respond better to treatment than older children," said Alberto Broniscer, M.D., assistant member in the St. Jude Department of Oncology and the paper's first author. "Unlike other previous studies in young children where the diagnosis of DPG was based on either CT scans or magnetic resonance imaging (MRI), the diagnosis of all our patients was based on MRI only. CT scans are not able to differentiate between DPG-a tumor that occurs in the brainstem-and other tumors, which originate in the same area with a better prognosis." The researchers reviewed the medical records of 10 patients under 3 years of age with DPG. The median age of these patients was 2.2 years, and the median time between symptom development and actual diagnosis was 2.5 months. All children had the diagnosis of DPG based on radiological review of their MRIs at diagnosis. All of the children received treatment-two with radiation, six with radiation plus chemotherapy, and two with chemotherapy only. Four of the children died, but six have survived for at least two years following this therapy, which is ineffective in older children with similar tumors. Based on these findings, the St. Jude team calculates that 45 percent of children under 3 years treated for DPG will survive for at least three years without experiencing tumor growth, and 69 percent of such children will survive. From these results, the investigators concluded that distinct biological characteristics of DPG in children under 3 years compared to older children might account for their better response to radiation and chemotherapy. The researchers point to a similar finding with a type of glioma that originates in the cerebrum: Young children with high-grade gliomas originating in the cerebrum seem to have a better prognosis when compared to older children. Different biological properties also seem to play a role in the latter case. Brainstem gliomas account for 10 to 15 percent of all brain tumors in children; and DPGs account for 80 percent of brainstem tumors in childhood. Although MRI revolutionized the diagnosis of DPG, no significant improvements have occurred in its treatment in children during the past 20 years, according to St. Jude researchers. The long-term survival of children with DPG has remained less than 10 percent despite treatment with radiation and chemotherapy. The St. Jude team is now collecting tumor samples and performing extensive molecular analyses in order to gain a better understanding of the biology of DPGs in children. "We believe that the more we learn about DPGs, the more likely we will be able to design more effective treatments for children of all ages with this tumor," Broniscer said. St. Jude Children's Research Hospital | |||||||||||||||||||||
|
Related Brain Tumor Current Events and Brain Tumor News Articles Pediatric study finds alternatives for radiation of low-grade brain tumors A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. New approach to gene therapy may shrink brain tumors, prevent their spread Massachusetts General Hospital (MGH) researchers are investigating a new approach to gene therapy for brain tumors - delivering a cancer-fighting gene to normal brain tissue around the tumor to keep it from spreading. Family history of brain tumors linked to increased risk of brain cancer People with a family history of cancerous brain tumors appear to be at higher risk of developing the same kind of tumors compared to people with no such family history. Barrow researchers identify a new approach to detect the early progression of brain tumors Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear. Childhood brain tumor traced to normal stem cells gone bad An aggressive childhood brain tumor known as medulloblastoma originates in normal brain "stem" cells that turn malignant when acted on by a known mutant, cancer-causing oncogene, say researchers from Dana-Farber Cancer Institute and the University of California, San Francisco (UCSF). Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors. Certain anticancer agents could be harmful to patients with heart disease A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis. Brown Chemists Create Cancer-Detecting Nanoparticles A team led by a Brown University chemist has created the smallest iron oxide nanoparticles to date for cancer detection by magnetic resonance imaging (MRI). The magnetic nanoparticles operate like tiny guided missiles, seeking and attaching themselves to malignant tumor cells. Once they bind, the particles emit stronger signals that MRI scans can detect. MRI: A window to genetic properties of brain tumors Doctors diagnose and prescribe treatment for brain tumors by studying, under a microscope, tumor tissue and cell samples obtained through invasive biopsy or surgery. Protein protects embryonic stem cells' versatility and self-renewal A protein known as REST blocks the expression of a microRNA that prevents embryonic stem cells from reproducing themselves and causes them to differentiate into specific cell types, scientists at The University of Texas M. D. Anderson Cancer Center report in the journal Nature. More Brain Tumor Current Events and Brain Tumor News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||